14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0001 $0.0001 Wednesday, 19th Apr 2023 GNCA stock ended at $0.0001. During the day the stock fluctuated 0% from a day low at $0.0001 to a day high of $0.0001.
90 days $0.0001 $0.0001
52 weeks $0.0001 $0.469

Historical Genocea Biosciences prices

Date Open High Low Close Volume
Feb 06, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Feb 03, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Feb 02, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Feb 01, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 31, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 30, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 27, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 26, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 25, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 24, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 23, 2023 $0.0001 $0.0001 $0.0001 $0.0001 0
Jan 20, 2023 $0.0001 $0.0001 $0.0001 $0.0001 9 316
Jan 19, 2023 $0.0001 $0.0001 $0.0001 $0.0001 3 400
Jan 18, 2023 $0.0001 $0.0001 $0.0001 $0.0001 2 718
Jan 17, 2023 $0.0001 $0.0001 $0.0001 $0.0001 12 538
Jan 13, 2023 $0.0001 $0.0001 $0.0001 $0.0001 61 824
Jan 12, 2023 $0.0001 $0.0001 $0.0001 $0.0001 596
Jan 11, 2023 $0.0001 $0.0064 $0.0001 $0.0001 15 239
Jan 10, 2023 $0.0001 $0.0001 $0.0001 $0.0001 7 376
Jan 09, 2023 $0.0001 $0.0064 $0.0001 $0.0001 186 133
Jan 06, 2023 $0.0001 $0.0001 $0.0001 $0.0001 9 030
Jan 05, 2023 $0.0006 $0.0006 $0.0006 $0.0006 0
Jan 04, 2023 $0.0006 $0.0006 $0.0006 $0.0006 0
Jan 03, 2023 $0.0006 $0.0006 $0.0006 $0.0006 0
Dec 30, 2022 $0.0006 $0.0006 $0.0006 $0.0006 0
Click to get the best stock tips daily for free!

About Genocea Biosciences

Genocea Biosciences Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of so... GNCA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT